Table 3.

Multivariate analysis to predict independent factors associated with 30-day mortality.

Variable		Overall Mortality		P-value
		HR	95% CI
Age (for every 1 year increase)		1.03	1.01, 1.06	0.01
Sex	Male	1.0	(Reference)	0.76
	Female	0.93	0.57, 1.51
Race	White	1.0	(Reference)	0.95
	Black	0.92	0.41, 2.07
	Other	1.15	0.32, 4.06
Insurance	Not insured	1.0	(Reference)	0.44
	Private/Managed care	2.62	0.95, 7.24
	Medicaid	1.36	0.61, 3.04
	Medicare	1.15	0.72, 1.82
	Other government	1.07	0.21, 5.58
Origin	Non-Hispanic	1.0	(Reference)	0.11
	Hispanic	1.95	0.85, 4.45
Grade	Well differentiated	1.0	(Reference)	0.10
	Moderately differentiated	1.08	0.55, 2.11
	Poorly differentiated	0.67	0.33, 1.36
	Undifferentiated	0.46	0.11, 1.88
Histological type	Adenocarcinoma	1.0	(Reference)	0.18
	Squamous cell carcinoma	1.20	0.73, 1.96
	Other	2.03	1.10, 3.66
CDCC score+	0	1.0	(Reference)	0.08
	1	1.12	0.73, 1.71
	2	2.01	1.10, 3.66
Behavior	In-situ cancer	1.0	(Reference)	0.70
	Invasive cancer	2.00	0.06, 69.55
AJCC stage	Stage 0	1.0	(Reference)	0.19
	Stage I	0.61	0.35, 1.04
	Stage II	0.75	0.46, 1.23
	Stage III	0.53	0.30, 0.94
	Stage IV	0.98	0.31, 3.16
Year of diagnosis	2010	1.0	(Reference)	0.61
	2011	0.91	0.64, 1.30
Margins	Negative	1.0	(Reference)	<0.001
	Positive	2.57	1.50, 4.41
Neoadjuvant radiation	No	1.0	(Reference)	0.70
	Yes	1.16	0.55, 2.42
Neoadjuvant chemotherapy	No	1.0	(Reference)	0.34
	Yes	0.70	0.33, 1.46
Surgical approach	MIE	1.0	(Reference)	0.78
	OE	1.06	0.70, 1.62

⁺Charlson–Deyo Comorbidity score. CI, confidence interval.